Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A 13C NMR study

Neurochemistry International

Volumn 92, Issue , 2016, Pages 25-34

  Bagga, Puneet ^a,b   Chugani, Anup N ^a   Patel, Anant B ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

1H 13C NMR; CMRGlc; GABA; Glutamate; Metabolism; Movement disorder; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; AMINO ACID; BRAIN EXTRACT; CAFFEINE; GLUCOSE; INOSITOL; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL OBSERVATION; BRAIN CORTEX; CARBON NUCLEAR MAGNETIC RESONANCE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; GABAERGIC TRANSMISSION; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLUTAMATERGIC SYNAPSE; GRIP STRENGTH; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; OLFACTORY BULB; PARKINSON DISEASE; PAW; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; DRUG EFFECTS; HAND STRENGTH; METABOLISM; MPTP POISONING; NEOSTRIATUM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

AMINO ACIDS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CAFFEINE; GAMMA-AMINOBUTYRIC ACID; GLUCOSE; HAND STRENGTH; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEOSTRIATUM; NEUROPROTECTIVE AGENTS;

EID: 84954074747     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2015.11.006     Document Type: Article

References (65)

1. J.D. Adams Jr., M.L. Chang, and L. Klaidman Parkinson's disease-redox mechanisms Curr. Med. Chem. 8 7 2001 809 814
2. L.M. Aguiar, H.V.J. Nobre, D.S. Macedo, A.A. Oliveira, R.M. Freitas, S.M. Vasconcelos, and et al. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats Pharmacol. Biochem. Behav. 84 3 2006 415 419
3. D. Alvarez-Fischer, J. Fuchs, F. Castagner, O. Stettler, O. Massiani-Beaudoin, K.L. Moya, and et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults Nat. Neurosci. 14 10 2011 1260 1266
4. A. Ascherio, S.M. Zhang, M.A. Hernan, I. Kawachi, G.A. Colditz, F.E. Speizer, and et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women Ann. Neurol. 50 1 2001 56 63
5. P. Bagga, and A.B. Patel Regional cerebral metabolism in mouse under chronic manganese exposure: implications for manganism Neurochem. Int. 60 2 2012 177 185
6. P. Bagga, A.N. Chugani, K.S. Varadarajan, and A.B. Patel In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment J. Neurochem. 127 3 2013 365 377
7. J. Blanchard, and S.J. Sawers The absolute bioavailability of caffeine in man Eur. J. Clin. Pharmacol. 24 1 1983 93 98
8. M. Bonati, R. Latini, F. Galletti, J.F. Young, G. Tognoni, and S. Garattini Caffeine disposition after oral doses Clin. Pharmacol. Ther. 32 1 1982 98 106
9. M. Bonati, R. Latini, G. Tognoni, J.F. Young, and S. Garattini Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat, and mouse Drug Metab. Rev. 15 7 1984 1355 1383
10. P. Borghammer, P. Cumming, K. Ostergaard, A. Gjedde, A. Rodell, C.J. Bailey, and et al. Cerebral oxygen metabolism in patients with early Parkinson's disease J. Neurol. Sci. 313 1-2 2012 123 128
11. L. Chang, S.M. Munsaka, S. Kraft-Terry, and T. Ernst Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain J. Neuroimmune Pharmacol. 8 3 2013 576 593
12. X. Chen, X. Lan, I. Roche, R. Liu, and J.D. Geiger Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum J. Neurochem. 107 4 2008 1147 1157
13. J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies J. Alzheimers Dis. 20 Suppl. 1 2010 S221 S238
14. 1H-MRS study on 6-OHDA and alpha-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker NMR Biomed. 26 1 2013 43 50
15. R.L. Doty Olfactory dysfunction in Parkinson disease Nat. Rev. Neurol. 8 6 2012 329 339
16. U.E. Emir, P.J. Tuite, and G. Oz Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS PLoS One 7 1 2012 e30918
17. 13C-edited NMR spectroscopy J. Cereb. Blood Flow. Metab. 10 2 1990 170 179
18. B.B. Fredholm, K. Battig, J. Holmen, A. Nehlig, and E.E. Zvartau Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol. Rev. 51 1 1999 83 133
19. M.S. Gevaerd, R.N. Takahashi, R. Silveira, and C. Da Cunha Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats Brain Res. Bull. 55 1 2001 101 106
20. G.E. Gibson, A.E. Kingsbury, H. Xu, J.G. Lindsay, S. Daniel, O.J. Foster, and et al. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease Neurochem. Int. 43 2 2003 129 135
21. 13C]-NMR spectroscopy of cerebral metabolism NMR Biomed. 16 6-7 2003 339 357
22. 13C]-NMR spectroscopy Magn. Reson Med. 49 2003 37 46
23. A. Ho Two wrongs make a right: nicotine and caffeine as defensive agents against Parkinson's disease Nutr. Bytes 8 2 2002
24. I. Husarova, O.V. Lungu, R. Marecek, M. Mikl, T. Gescheidt, P. Krupa, and et al. Functional imaging of the cerebellum and basal ganglia during predictive motor timing in early Parkinson's disease J. Neuroimag. 24 1 2011 45 53
25. F. Hyder, A.B. Patel, A. Gjedde, D.L. Rothman, K.L. Behar, and R.G. Shulman Neuronal-glial glucose oxidation and glutamatergic-GABAergic function J. Cereb. Blood Flow. Metab. 26 7 2006 865 877 10.1038/sj.jcbfm.9600263
26. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 Suppl. 3 2003 S26 S36 discussion S-8
27. P. Jenner From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease Park. Relat. Disord. 15 Suppl. 4 2009 S18 S23
28. H. De Jesus-Cortes, P. Xu, J. Drawbridge, S.J. Estill, P. Huntington, S. Tran, and et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease Proc. Natl. Acad. Sci. U. S. A. 109 42 2012 17010 17015
29. M.T. Joghataie, M. Roghani, F. Negahdar, and L. Hashemi Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence Park. Relat. Disord. 10 8 2004 465 468
30. A. Kachroo, M.C. Irizarry, and M.A. Schwarzschild Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration Exp. Neurol. 223 2 2010 657 661
31. G.B. Kaplan, N.T. Tai, D.J. Greenblatt, and R.I. Shader Caffeine-induced behavioural stimulation is dose- and concentration-dependent Br. J. Pharmacol. 100 3 1990 435 440
32. M. Kohutnicka, E. Lewandowska, I. Kurkowska-Jastrzebska, A. Czlonkowski, and A. Czlonkowska Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Immunopharmacology 39 3 1998 167 180
33. 18F]fluorodeoxyglucose method Ann. Neurol. 15 5 1984 419 424
34. K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J.Q. Trojanowski, and et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice Science 338 6109 2012 949 953
35. J.A. Machado-Filho, A.O. Correia, A.B. Montenegro, M.E. Nobre, G.S. Cerqueira, K.R. Neves, and et al. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions Behav. Brain Res. 264 2014 116 125
36. G.E. Meredith, and D.J. Rademacher MPTP mouse models of Parkinson's disease: an update J. Park. Dis. 1 1 2011 19 33
37. M. Mohanasundari, M.S. Srinivasan, S. Sethupathy, and M. Sabesan Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice J. Neurol. Sci. 249 2 2006 140 144
38. M. Morelli, A.R. Carta, and P. Jenner Adenosine A2A receptors and Parkinson's disease Handb. Exp. Pharmacol. 193 2009 589 615
39. D.M. Morens, J.W. Davis, A. Grandinetti, G.W. Ross, J.S. Popper, and L.R. White Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men Neurology 46 4 1996 1044 1050
40. A. Nehlig Are we dependent upon coffee and caffeine? A review on human and animal data Neurosci. Biobehav Rev. 23 4 1999 563 576
41. E. Palombo, L.J. Porrino, A.M. Crane, K.S. Bankiewicz, I.J. Kopin, and L. Sokoloff Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys J. Neurochem. 56 5 1991 1639 1646
42. A.B. Patel, D.L. Rothman, G.W. Cline, and K.L. Behar Glutamine is the major precursor for GABA synthesis in rat neocortex in vivo following acute GABA-transaminase inhibition Brain Res. 919 2 2001 207 220
43. A.B. Patel, R.A. de Graaf, G.F. Mason, T. Kanamatsu, D.L. Rothman, R.G. Shulman, and et al. Glutamatergic neurotransmission and neuronal glucose oxidation are coupled during intense neuronal activation J. Cereb. Blood Flow. Metab. 24 9 2004 972 985
44. A.B. Patel, R.A. de Graaf, G.F. Mason, D.L. Rothman, R.G. Shulman, and K.L. Behar The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex in vivo Proc. Natl. Acad. Sci. U. S. A. 102 15 2005 5588 5593
45. V.H. Perry, J.A. Nicoll, and C. Holmes Microglia in neurodegenerative disease Nat. Rev. Neurol. 6 4 2010 193 201
46. M. Pierri, E. Vaudano, T. Sager, and U. Englund KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacology 48 4 2005 517 524
47. R.D. Prediger Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms J. Alzheimers Dis. 20 Suppl. 1 2010 S205 S220
48. N. Rebola, P.M. Canas, C.R. Oliveira, and R.A. Cunha Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat Neuroscience 132 4 2005 893 903
49. G.W. Ross, R.D. Abbott, H. Petrovitch, D.M. Morens, A. Grandinetti, K.H. Tung, and et al. Association of coffee and caffeine intake with the risk of Parkinson disease Jama 283 20 2000 2674 2679
50. D.L. Rothman, K.L. Behar, F. Hyder, and R.G. Shulman In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function Annu. Rev. Physiol. 65 2003 401 427
51. H. Russ, K. Staust, F. Martel, M. Gliese, and E. Schomig The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia Eur. J. Neurosci. 8 6 1996 1256 1264
52. N. Schmidt, and B. Ferger Neurochemical findings in the MPTP model of Parkinson's disease J. Neural Transm. 108 11 2001 1263 1282
53. N.R. Sibson, A. Dhankhar, G.F. Mason, D.L. Rothman, K.L. Behar, and R.G. Shulman Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity Proc. Natl. Acad. Sci. U. S. A. 95 1 1998 316 321
54. S. Singh, K. Singh, S.P. Gupta, D.K. Patel, V.K. Singh, R.K. Singh, and et al. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum Brain Res. 1283 2009 115 126
55. O.B. Smeland, M.G. Hadera, T.S. McDonald, U. Sonnewald, and K. Borges Brain mitochondrial metabolic dysfunction and glutamate level reduction in the pilocarpine model of temporal lobe epilepsy in mice J. Cereb. Blood Flow. Metab. 33 7 2013 1090 1097 10.1038/jcbfm.2013.54
56. R.J. Smeyne, and V. Jackson-Lewis The MPTP model of Parkinson's disease Brain Res. Mol. Brain Res. 134 1 2005 57 66
57. M.B. Spraker, J. Prodoehl, D.M. Corcos, C.L. Comella, and D.E. Vaillancourt Basal ganglia hypoactivity during grip force in drug naive Parkinson's disease Hum. Brain Mapp. 31 12 2010 1928 1941
58. P. Teismann, K. Tieu, O. Cohen, D.K. Choi, D.C. Wu, D. Marks, and et al. Pathogenic role of glial cells in Parkinson's disease Mov. Disord. official J. Mov. Disord. Soc. 18 2 2003 121 129 10.1002/mds.10332
59. V. Tiwari, S. Ambadipudi, and A.B. Patel Glutamatergic and GABAergic TCA cycle and neurotransmitter cycling fluxes in different regions of mouse brain J. Cereb. Blood Flow. Metab. 33 10 2013 1523 1531
60. V. Tiwari, P. Veeraiah, V. Subramaniam, and A.B. Patel Differential effects of ethanol on regional glutamatergic and GABAergic neurotransmitter pathways in mouse brain J. Neurochem. 128 5 2014 628 640 10.1111/jnc.12508
61. P. Veeraiah, J.M. Noronha, S. Maitra, P. Bagga, N. Khandelwal, S. Chakravarty, and et al. Dysfunctional glutamatergic and gamma-aminobutyric acidergic activities in prefrontal cortex of mice in social defeat model of depression Biol. Psychiatry 76 3 2014 231 238 10.1016/j.biopsych.2013.09.024
62. A. Wang, Y. Lin, Y. Wu, and D. Zhang Macronutrients intake and risk of Parkinson's disease: a meta-analysis Geriatr. Gerontol. Int. 15 5 2015 606 616
63. K. Xu, Y.H. Xu, J.F. Chen, and M.A. Schwarzschild Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease Neuroscience 167 2 2010 475 481
64. M.B. Youdim, E. Grunblatt, Y. Levites, G. Maor, and S. Mandel Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron Neurotox. Res. 4 7-8 2002 679 689 10.1080/1029842021000045507
65. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes Park. Relat. Disord. 18 Suppl. 1 2012 S60 S62